Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...
I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...
Pennsylvania was involved in a coalition of 50 states and territories that have settled with the generic prescription drug ...
Neurocrine Biosciences, Inc.'s potential for growth in the biopharma sector is strong despite recent setbacks, making its ...
In terms of liquidity and interest, the mean open interest for Teva Pharmaceutical Indus options trades today is 8263.67 with ...
high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. Receive News & Ratings for Teva Pharmaceutical ...
Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating third-quarter expectations and raising its guidance.
Attorney General Charity Clark announced two significant multistate settlements with Heritage Pharmaceuticals and Apotex which nationally total $49.1 million. The settlements resolve allegations that ...
Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...
On October 31, 2024, the European Commission (EC) fined Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva) ...